| 29240-9 |
Hyaluronate |
MCnc |
Body fld |
Pt |
Qn |
|
|
ACTIVE |
Hyaluronate [Mass/volume] in Body fluid |
|
MIN |
DefinitionDescription |
|
|
ng/mL |
|
|
|
|
|
|
DRUG/TOX |
|
29240-9 |
|
|
|
|
Both |
|
|
|
0 |
Hyaluronate Fld-mCnc |
|
|
|
N |
|
B/F; BF; bod; Bodies; Body fluid; Body fluid, unsp; DRUG/TOXICOLOGY; Drugs; Fl; Fld; FLU; Fluid; HA; Hyaluronan; Hyaluronic acid; Level; Mass concentration; Point in time; QNT; Quan; Quant; Quantitative; Random |
2.7 |
2.03 |
|
|
|
|
|
|
|
ng/mL |
|
|
|
0 |
| 29241-7 |
Mumps virus Ab.IgG |
ACnc |
Body fld |
Pt |
Qn |
|
|
ACTIVE |
Mumps virus IgG Ab [Units/volume] in Body fluid |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
MICRO |
|
29241-7 |
|
|
|
|
Both |
|
|
|
0 |
MuV IgG Fld-aCnc |
|
|
|
N |
|
ABS; Aby; Antby; Anti; Antibodies; Antibody; Arbitrary concentration; Autoantibodies; Autoantibody; B/F; BF; bod; Bodies; Body fluid; Body fluid, unsp; Fl; Fld; FLU; Fluid; ID; Immune globulin G; Immunoglobulin G; Infectious Disease; InfectiousDisease; Microbiology; MuV; Point in time; QNT; Quan; Quant; Quantitative; Random |
2.69 |
2.03 |
|
|
|
|
|
|
|
[arb'U]/mL |
|
|
|
0 |
| 29242-5 |
Measles virus Ab.IgG |
ACnc |
Body fld |
Pt |
Qn |
|
|
ACTIVE |
Measles virus IgG Ab [Units/volume] in Body fluid |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
MICRO |
|
29242-5 |
|
|
|
|
Both |
|
|
|
0 |
MeV IgG Fld-aCnc |
|
|
|
N |
|
ABS; Aby; Antby; Anti; Antibodies; Antibody; Arbitrary concentration; Autoantibodies; Autoantibody; B/F; BF; bod; Bodies; Body fluid; Body fluid, unsp; Fl; Fld; FLU; Fluid; ID; Immune globulin G; Immunoglobulin G; Infectious Disease; InfectiousDisease; MeV; Microbiology; Msls; Point in time; QNT; Quan; Quant; Quantitative; Random; Rubeola |
2.69 |
2.03 |
|
|
|
|
|
|
|
[arb'U]/mL |
|
|
|
0 |
| 29243-3 |
Thiodiglycolate |
MCnc |
Urine |
Pt |
Qn |
|
|
ACTIVE |
Thiodiglycolate [Mass/volume] in Urine |
|
MIN |
DefinitionDescription |
|
|
ug/mL |
|
|
|
|
|
|
DRUG/TOX |
|
29243-3 |
|
|
|
|
Both |
|
|
|
0 |
Thiodiglycolate Ur-mCnc |
|
|
|
N |
|
DRUG/TOXICOLOGY; Drugs; Level; Mass concentration; Mercaptodiacetate; Mercaptodiacetic acid; Point in time; QNT; Quan; Quant; Quantitative; Random; Thiodiglycolic acid; UA; UR; Urn |
2.73 |
2.03 |
|
|
|
|
|
|
|
ug/mL |
|
|
|
0 |
| 29244-1 |
Thiodiglycolate/Creatinine |
MRto |
Urine |
Pt |
Qn |
|
|
ACTIVE |
Thiodiglycolate/Creatinine [Mass Ratio] in Urine |
|
MIN |
DefinitionDescription |
|
|
mg/g creatinine |
|
|
|
|
|
|
DRUG/TOX |
|
29244-1 |
|
|
|
|
Both |
|
|
|
0 |
Thiodiglycolate/Creat Ur |
|
|
|
N |
|
CR; Crea; Creat; DRUG/TOXICOLOGY; Drugs; Mass concentration ratio; Mass ratio; MCRto; Mercaptodiacetate; Mercaptodiacetic acid; Point in time; QNT; Quan; Quant; Quantitative; Random; Thiodiglycolic acid; UA; UCr; UR; Urn |
2.73 |
2.03 |
|
|
|
|
|
|
|
mg/g{creat} |
|
|
|
0 |
| 29245-8 |
Zinc |
MCnt |
Nail |
Pt |
Qn |
|
|
ACTIVE |
Zinc [Mass/mass] in Nail |
|
MIN |
DefinitionDescription |
|
|
ug/g |
|
|
|
|
|
|
DRUG/TOX |
|
29245-8 |
|
|
|
|
Both |
|
|
|
0 |
Zinc Nail-mCnt |
|
|
|
N |
|
DRUG/TOXICOLOGY; Drugs; Mass content; Nails; Point in time; QNT; Quan; Quant; Quantitative; Random; Ungal nail; Zn |
2.73 |
2.03 |
|
|
|
|
|
|
|
ug/g |
|
|
|
0 |
| 29246-6 |
Lactate |
MCnc |
Body fld |
Pt |
Qn |
|
|
ACTIVE |
Lactate [Mass/volume] in Body fluid |
|
MIN |
DefinitionDescription |
|
|
mg/dL |
|
|
|
|
|
|
CHEM |
|
29246-6 |
|
|
|
|
Both |
|
|
|
0 |
Lactate Fld-mCnc |
|
|
|
N |
|
2-Hydroxypropanoic acid; 2-hydroxy-propionate; 2-hydroxy-propionic acid; B/F; BF; bod; Bodies; Body fluid; Body fluid, unsp; Chemistry; Fl; Fld; FLU; Fluid; Lact; Lactic acid; Level; L-lactate; Mass concentration; Point in time; QNT; Quan; Quant; Quantitative; Random |
2.73 |
2.03 |
|
|
|
|
|
|
|
mg/dL |
|
|
|
0 |
| 29247-4 |
Sirolimus |
MCnc |
Bld |
Pt |
Qn |
|
|
ACTIVE |
Sirolimus [Mass/volume] in Blood |
|
MIN |
DefinitionDescription |
|
|
ug/L;ng/mL |
|
|
|
|
|
|
DRUG/TOX |
|
29247-4 |
|
|
|
|
Both |
|
|
|
0 |
Sirolimus Bld-mCnc |
|
|
|
N |
|
Blood; DRUG/TOXICOLOGY; Drugs; Level; Mass concentration; Point in time; QNT; Quan; Quant; Quantitative; Random; Rapamune; Rapamycin; SRL; UniversalLabOrders; WB; Whole blood |
2.73 |
2.03 |
|
|
|
|
|
|
|
ng/mL |
|
|
|
0 |
| 29248-2 |
Varicella zoster virus DNA |
PrThr |
Bld |
Pt |
Ord |
Probe.amp.tar |
|
ACTIVE |
Varicella zoster virus DNA [Presence] in Blood by NAA with probe detection |
|
MIN |
DefinitionDescription |
|
|
|
Not detected |
|
|
|
|
|
MICRO |
|
29248-2 |
|
Probe.amp.tar |
|
|
Both |
|
|
|
0 |
VZV DNA Bld Ql NAA+probe |
|
|
|
N |
|
3 Self-Sustaining Sequence Replication; 3SR SR; Amplif; Amplification; Amplified; Blood; Chicken pox; Chicken pox virus; Chickenpox; Deoxyribonucleic acid; DNA NUCLEIC ACID PROBE; DNA probe; Herpes zoster; HHV-3; Human herpesvirus 3; ID; Infectious Disease; InfectiousDisease; LAT; LCR; Ligase chain reaction; Ligation-activated transcription; Microbiology; NAA+probe; NAAT; NASBA; Nucleic acid sequence based analysis; Ordinal; PCR; Point in time; Polymerase chain reaction; PR; Probe amp; Probe with ampification; Probe with target amplification; QBR; QL; Qual; Qualitative; Random; Screen; SDA; Shingles; Strand Displacement Amplification; TMA; Transcription mediated amplification; VZ; VZV; WB; Whole blood; Zoster |
2.73 |
2.03 |
|
|
|
|
|
|
|
|
|
|
The PrThr property is used for LOINC terms whose results are reported using an ordered categorical scale, regardless of whether or not an internal threshold was used to make that determination. This change was approved by the Laboratory LOINC Committee in June 2016. |
0 |
| 29249-0 |
Varicella zoster virus Ab.IgG |
ACnc |
Body fld |
Pt |
Qn |
|
|
ACTIVE |
Varicella zoster virus IgG Ab [Units/volume] in Body fluid |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
MICRO |
|
29249-0 |
|
|
|
|
Both |
|
|
|
0 |
VZV IgG Fld-aCnc |
|
|
|
N |
|
ABS; Aby; Antby; Anti; Antibodies; Antibody; Arbitrary concentration; Autoantibodies; Autoantibody; B/F; BF; bod; Bodies; Body fluid; Body fluid, unsp; Chicken pox; Chicken pox virus; Chickenpox; Fl; Fld; FLU; Fluid; Herpes zoster; HHV-3; Human herpesvirus 3; ID; Immune globulin G; Immunoglobulin G; Infectious Disease; InfectiousDisease; Microbiology; Point in time; QNT; Quan; Quant; Quantitative; Random; Shingles; VZ; VZV; Zoster |
2.69 |
2.03 |
|
|
|
|
|
|
|
[arb'U]/mL |
|
|
|
0 |
| 2925-6 |
Ribonuclease |
CCnc |
Ser |
Pt |
Qn |
|
|
ACTIVE |
Ribonuclease [Enzymatic activity/volume] in Serum |
|
MIN |
DefinitionDescription |
|
|
arb U/L |
|
|
|
|
|
|
CHEM |
|
2925-6 |
|
|
|
|
Both |
|
|
|
0 |
RNase Ser-cCnc |
|
|
|
Y |
|
Catalytic Concentration; Chemistry; Point in time; QNT; Quan; Quant; Quantitative; Random; RNase; Serum; SR |
2.68 |
1 |
|
|
|
|
|
|
|
U/L |
|
|
|
0 |
| 29250-8 |
Brucella sp Ab^1st specimen |
Titr |
Ser |
Pt |
SemiQn |
|
|
ACTIVE |
Brucella sp Ab [Titer] in Serum --1st specimen |
|
MAJ |
DefinitionDescription |
|
|
titer |
1:80 |
|
|
|
|
|
MICRO |
|
29250-8 |
|
|
|
|
Both |
|
|
|
0 |
Brucella Ab sp1 Titr Ser |
|
|
|
N |
|
ABS; Aby; Acute specimen; Antby; Anti; Antibodies; Antibody; Autoantibodies; Autoantibody; Bruc; Brucellosis; Dilution factor; Dilution Factor (Titer); First; ID; Infectious Disease; InfectiousDisease; Microbiology; Point in time; Pre immunization; Random; Serum; SmQn; sp1; Spec; species; spp; SR; Titer; Titered; Titre; Ttr |
2.75 |
2.03 |
|
|
|
|
|
|
|
{titer} |
|
|
|
0 |
| 29251-6 |
Brucella sp Ab^2nd specimen |
Titr |
Ser |
Pt |
SemiQn |
|
|
ACTIVE |
Brucella sp Ab [Titer] in Serum --2nd specimen |
|
MAJ |
DefinitionDescription |
|
|
titer |
1:80 |
|
|
|
|
|
MICRO |
|
29251-6 |
|
|
|
|
Both |
|
|
|
0 |
Brucella Ab sp2 Titr Ser |
|
|
|
N |
|
ABS; Aby; Antby; Anti; Antibodies; Antibody; Autoantibodies; Autoantibody; Bruc; Brucellosis; Convalescent; Dilution factor; Dilution Factor (Titer); ID; Infectious Disease; InfectiousDisease; Microbiology; Point in time; Post immunization; Random; Second; Serum; SmQn; sp2; Spec; species; spp; SR; Titer; Titered; Titre; Ttr |
2.75 |
2.03 |
|
|
|
|
|
|
|
{titer} |
|
|
|
0 |
| 29252-4 |
Multisection^WO contrast |
Find |
Chest |
Pt |
Doc |
CT |
|
ACTIVE |
CT Chest WO contrast |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
RAD |
|
29252-4 |
|
CT |
|
|
Both |
|
|
|
0 |
CT Chest WO contr |
|
|
|
N |
|
c; CAT scan; Computed tomography; Computerized tomography; Contr; Contra; Contrst; CorePlaybook; CT scan; Document; Finding; Findings; Imaging; Playbook; Point in time; Rad; Radiology; Random; Thorax; without contrast |
2.73 |
2.03 |
|
|
|
|
|
|
|
|
|
|
The scale has been changed from "Nar" to "Doc" to fit with the CDA model. |
0 |
| 29253-2 |
Alpha-1-Fetoprotein^^adjusted |
MoM |
Amnio fld |
Pt |
Qn |
|
|
ACTIVE |
Alpha-1-Fetoprotein [Multiple of the median] adjusted in Amniotic fluid |
|
MIN |
DefinitionDescription |
|
|
M.o.M |
|
|
|
|
|
|
CHEM |
|
29253-2 |
|
|
|
|
Observation |
|
|
|
0 |
AFP adj MoM Amn |
|
|
|
N |
|
A1; adj; AF; AFAFP; AFP; Alfa; Alpha fetoprotein; Alphafetoprotein; Amn; Amn fl; Amnio; Amniotic flu; Amniotic fluid; Chemistry; Feto; Gyn; Gynecology; i; MoM; Multiple of the median; OB; ObGyn; Obstetrics; Point in time; QNT; Quan; Quant; Quantitative; Random; Tumor marker |
2.73 |
2.03 |
|
|
|
|
|
|
|
{M.o.M} |
|
|
|
0 |
| 29254-0 |
Linezolid |
Susc |
Isolate |
Pt |
OrdQn |
MIC |
|
ACTIVE |
Linezolid [Susceptibility] by Minimum inhibitory concentration (MIC) |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
ABXBACT |
|
29254-0 |
|
MIC |
|
|
Observation |
|
|
|
0 |
Linezolid Islt MIC |
|
|
|
N |
|
ANTIBIOTIC SUSCEPTIBILITIES; AST; ID; Infectious Disease; InfectiousDisease; Islt; Isol; Minimum inhibitory concentration; Point in time; Random; Sus; Suscept; Susceptibilities; Susceptibility; Susceptibilty; Zyvox |
2.73 |
2.03 |
|
|
|
|
|
|
|
|
|
|
|
0 |
| 29255-7 |
Linezolid |
Susc |
Isolate |
Pt |
OrdQn |
Agar diffusion |
|
ACTIVE |
Linezolid [Susceptibility] by Disk diffusion (KB) |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
ABXBACT |
|
29255-7 |
|
Agar diffusion |
|
|
Observation |
|
|
|
0 |
Linezolid Islt KB |
|
|
|
N |
|
ANTIBIOTIC SUSCEPTIBILITIES; AST; Disk diffusion; ID; Infectious Disease; InfectiousDisease; Islt; Isol; KB; Kirby-bauer; Point in time; Random; Sus; Suscept; Susceptibilities; Susceptibility; Susceptibilty; Zyvox |
2.73 |
2.03 |
|
|
|
|
|
|
|
|
|
|
|
0 |
| 29256-5 |
Fat.microscopic observation |
Prid |
Urine sed |
Pt |
Nom |
Sudan IV stain |
|
ACTIVE |
Fat.microscopic observation [Identifier] in Urine sediment by Sudan IV stain |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
UA |
|
29256-5 |
|
Sudan IV stain |
|
|
Observation |
|
|
|
0 |
Fat UrnS Sudan IV Stn |
|
|
|
N |
|
Identity or presence; Kidney; Nephrology; Nominal; Point in time; Random; Renal; St; Stains; Stn; Sudan IV Stn; Sudn; UA; UR; URINALYSIS; Urine sediment; Urn; UrnS |
2.73 |
2.03 |
|
|
|
|
|
|
|
|
|
|
|
0 |
| 29257-3 |
Mycoplasma pneumoniae DNA |
PrThr |
XXX |
Pt |
Ord |
Probe.amp.tar |
|
ACTIVE |
Mycoplasma pneumoniae DNA [Presence] in Specimen by NAA with probe detection |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
MICRO |
|
29257-3 |
|
Probe.amp.tar |
|
|
Both |
|
|
|
0 |
M pneumo DNA Spec Ql NAA+probe |
|
|
|
N |
|
3 Self-Sustaining Sequence Replication; 3SR SR; Amplif; Amplification; Amplified; Deoxyribonucleic acid; DNA NUCLEIC ACID PROBE; DNA probe; Enzootic pneumonia; ID; Infectious Disease; InfectiousDisease; LAT; LCR; Ligase chain reaction; Ligation-activated transcription; M pneumo; M pneumonia; M pneumoniae; Microbiology; Misc; Miscellaneous; Myco; Myco pneu; Mycoplas; Mycoplasm; Mycoplasmoides pneumoniae; Mycoplasmosis; Mycoplsm; NAA+probe; NAAT; NASBA; Nucleic acid sequence based analysis; Ordinal; Other; PCR; Pneu; pneum; Pneumo; Pneumon; Pneumonia; Point in time; Polymerase chain reaction; PR; Probe amp; Probe with ampification; Probe with target amplification; QBR; QL; Qual; Qualitative; Random; Screen; SDA; Spec; Strand Displacement Amplification; TMA; To be specified in another part of the message; Transcription mediated amplification; UniversalLabOrders; Unspecified |
2.73 |
2.03 |
|
|
|
|
|
|
|
|
|
|
The PrThr property is used for LOINC terms whose results are reported using an ordered categorical scale, regardless of whether or not an internal threshold was used to make that determination. This change was approved by the Laboratory LOINC Committee in June 2016. |
0 |
| 29258-1 |
Linezolid |
Susc |
Isolate |
Pt |
OrdQn |
|
|
ACTIVE |
Linezolid [Susceptibility] |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
ABXBACT |
|
29258-1 |
|
|
|
|
Observation |
|
|
|
0 |
Linezolid Susc Islt |
|
|
|
N |
|
ANTIBIOTIC SUSCEPTIBILITIES; AST; ID; Infectious Disease; InfectiousDisease; Islt; Isol; Point in time; Random; Sus; Suscept; Susceptibilities; Susceptibility; Susceptibilty; Zyvox |
2.73 |
2.03 |
|
|
|
|
|
|
|
|
|
|
|
0 |
| 29259-9 |
Monocytes.abnormal/Leukocytes |
NFr |
Bld |
Pt |
Qn |
Manual count |
|
ACTIVE |
Monocytes Abnormal/Leukocytes in Blood by Manual count |
|
NAM |
DefinitionDescription |
|
|
% |
|
|
|
|
|
|
HEM/BC |
|
29259-9 |
|
Manual count |
|
|
Observation |
|
|
|
0 |
Abn Monocytes NFr Bld Manual |
|
|
|
N |
|
abn; Abn Monocytes; abnorm; Blood; HEMATOLOGY/CELL COUNTS; Leuc; Leuk; Leukocyte; Lkcs; Manl; Mono; Monocyte; Monos; Number fraction; Percent; Point in time; QNT; Quan; Quant; Quantitative; Random; WB; WBC; WBCs; White blood cell; White blood cells; Whole blood |
2.79 |
2.03 |
|
|
|
|
|
|
|
% |
|
|
Release 2.79: COMPONENT: Triggered by Coll w SCT: This is a specific fraction case where the denominator is percentage or /100. Because the logic is that the percentage piece is captured by Property: NFr (Numeric Fraction), and by Unit: %, therefore, it is redundant to include "100" in the component; |
0 |
| 2926-4 |
Ribose |
MCnc |
Ser |
Pt |
Qn |
|
|
ACTIVE |
Ribose [Mass/volume] in Serum |
|
MIN |
DefinitionDescription |
|
|
mg/dL |
|
|
|
|
|
|
CHEM |
|
2926-4 |
|
|
|
|
Both |
|
|
|
0 |
Ribose Ser-mCnc |
|
|
|
Y |
|
Chemistry; D-ribose; Level; Mass concentration; Point in time; QNT; Quan; Quant; Quantitative; Random; Serum; SR |
2.42 |
1 |
|
|
|
|
|
|
|
mg/dL |
|
|
|
0 |
| 29260-7 |
Monocytes.abnormal |
NCnc |
Bld |
Pt |
Qn |
Manual count |
|
ACTIVE |
Monocytes Abnormal [#/volume] in Blood by Manual count |
|
MIN |
DefinitionDescription |
|
|
10*9/L |
|
|
|
|
|
|
HEM/BC |
|
29260-7 |
|
Manual count |
|
|
Observation |
|
|
|
0 |
Abn Monocytes # Bld Manual |
|
|
|
N |
|
#; abn; Abn Monocytes; abnorm; ABS; absolute; absolutes; Blood; Cnt; Count; Count/volume; CT; HEMATOLOGY/CELL COUNTS; Manl; Mono; Monocyte; Monos; Number concentration; Number Concentration (count/vol); Point in time; QNT; Quan; Quant; Quantitative; Random; WB; Whole blood |
2.4 |
2.03 |
|
|
|
|
|
|
|
10*3/uL |
|
|
|
0 |
| 29261-5 |
Lymphocytes.abnormal/Leukocytes |
NFr |
Bld |
Pt |
Qn |
Manual count |
|
ACTIVE |
Abnormal lymphocytes/Leukocytes in Blood by Manual count |
|
NAM |
DefinitionDescription |
|
|
% |
|
|
|
|
|
|
HEM/BC |
|
29261-5 |
|
Manual count |
|
|
Observation |
|
|
|
0 |
Lymph Abn NFr Bld Manual |
|
|
|
N |
|
abn; abnorm; Atypical; Blood; HEMATOLOGY/CELL COUNTS; Leuc; Leuk; Leukocyte; Lkcs; Lymp; Lymph; Lymph Abn; Lympho; Lymphocyte; Lymphs; Lymphs%; Manl; Number fraction; Percent; Point in time; QNT; Quan; Quant; Quantitative; Random; WB; WBC; WBCs; White blood cell; White blood cells; Whole blood |
2.79 |
2.03 |
|
|
|
|
|
|
|
% |
|
|
Release 2.79: COMPONENT: Triggered by Coll w SCT: This is a specific fraction case where the denominator is percentage or /100. Because the logic is that the percentage piece is captured by Property: NFr (Numeric Fraction), and by Unit: %, therefore, it is redundant to include "100" in the component; |
0 |
| 29262-3 |
Lymphocytes.abnormal |
NCnc |
Bld |
Pt |
Qn |
Manual count |
|
ACTIVE |
Abnormal lymphocytes [#/volume] in Blood by Manual count |
|
MIN |
DefinitionDescription |
|
|
10*9/L |
|
|
|
|
|
|
HEM/BC |
|
29262-3 |
|
Manual count |
|
|
Observation |
|
|
|
0 |
Lymph Abn # Bld Manual |
|
|
|
N |
|
#; abn; abnorm; ABS; absolute; absolutes; Atypical; Blood; Cnt; Count; Count/volume; CT; HEMATOLOGY/CELL COUNTS; Lymp; Lymph; Lymph Abn; Lympho; Lymphocyte; Lymphs; Lymphs%; Manl; Number concentration; Number Concentration (count/vol); Point in time; QNT; Quan; Quant; Quantitative; Random; WB; Whole blood |
2.73 |
2.03 |
|
|
|
|
|
|
|
10*3/uL |
|
|
|
0 |
